We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Ovid Therapeutics Inc | NASDAQ:OVID | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.01 | -0.33% | 3.06 | 3.00 | 3.35 | 3.17 | 3.00 | 3.17 | 77,179 | 00:00:00 |
The presentations available on the AAN Science Highlights online platform include the following:
Presentations on OV101 (gaboxadol) in Neurodevelopmental Disorders:
Title: The adaptation and utility of the Clinical Global Impression scale for studying treatment outcomes in neurodevelopmental conditions Topic: Child Neurology and Developmental Neurology
Title: The pivotal Phase 3 NEPTUNE trial investigating OV101 (gaboxadol) in Angelman syndrome: study overview and rationale Topic: Child Neurology and Developmental Neurology
Title: Evidence of pharmacodynamic tolerance during repeated daily OV101 (gaboxadol) exposure in individuals with Angelman syndrome Topic: Child Neurology and Developmental Neurology
Title: Physiologically based pharmacokinetic modeling (PBPK) for OV101 (gaboxadol) exposure in children with Angelman syndrome Topic: Child Neurology and Developmental Neurology
Title: Caregiver insight on the core domains in Angelman syndrome Topic: Child Neurology and Developmental Neurology
Title: Quality of life in adolescent and adult individuals with Angelman syndrome: Baseline results from the Phase 2 STARS study Topic: Child Neurology and Developmental Neurology
Title: Concomitant medication in adolescent and adult individuals with Angelman syndrome: Baseline results from the Phase 2 STARS study Topic: Child Neurology and Developmental Neurology
Title: The Phase 2a ROCKET trial investigating OV101 (gaboxadol) in adolescents and young adults with Fragile X syndrome Topic: Child Neurology and Developmental Neurology
Presentations on OV935/TAK935 (soticlestat) in Rare Developmental and Epileptic Encephalopathies (DEE):
Title: Initial data from the ongoing ENDYMION open-label extension trial of soticlestat (TAK-935/OV935) in participants with developmental and/or epileptic encephalopathies (DEE) Topic: Epilepsy/Clinical Neurophysiology (EEG)
Title: A phase 1b/2a study of soticlestat (TAK-935/OV935) as adjunctive therapy in patients with developmental and epileptic encephalopathies Topic: Epilepsy/Clinical Neurophysiology (EEG)
About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. Ovid has a broad pipeline of potential first-in-class medicines. The Company’s most advanced investigational medicine, OV101 (gaboxadol), is currently in clinical development for the treatment of Angelman syndrome and Fragile X syndrome. Ovid is also developing OV935/TAK935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited for the potential treatment of rare developmental and epileptic encephalopathies (DEE).
For more information on Ovid, please visit http://www.ovidrx.com/.
Contacts
Investors and Media:Ovid Therapeutics Inc.Investor Relations & Public Relationsirpr@ovidrx.com
Or
Investors: Steve KlassBurns McClellan, Inc.sklass@burnsmc.com (212) 213-0006
Media: Katie Engleman 1AB katie@1abmedia.com (919) 333-7722
1 Year Ovid Therapeutics Chart |
1 Month Ovid Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions